Almaarefa University
The authoritative source for research information and outputs is Elsevier Scopus, with researcher profile verification from the Deanship of Scientific Research.

المخرجات

Research outputs

Articles, reviews, conference papers and book chapters, indexed by DOI and linked to University researchers.

38 output Results for «Neuroscience»

ArticleOpen access20261citation· Semantic Scholar

GLP-1 receptor agonists as potential disease-modifying agents in Parkinson’s and Alzheimer’s disease: mechanisms, clinical trial evidence, and the neuroprotection horizon

Frontiers in Aging Neuroscience · vol. 18

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), originally developed as antidiabetic agents, have emerged as candidate disease-modifying therapies for Parkinson’s disease (PD) and Alzheimer’s disease (AD), reflecting the widespread expression of GLP-1 receptors across neurons, glia, and the cerebral vasculature. This narrative review synthesizes mechanistic, clinical trial, and biomarker evidence for GLP-1 RAs in PD and AD, based on a literature search of PubMed, Embase, Scopus, and Web of Science, with ClinicalTrials.gov searched separately for trial protocols and results, through May 2026. Preclinical data implicate GLP-1 receptor agonism in anti-neuroinflammatory signaling, mitochondrial preservation, autophagy and proteostasis enhancement, anti-apoptotic effects, synaptic plasticity, cerebrovascular protection, and glymphatic clearance. Clinical evidence in PD is mixed and agent- and formulation-dependent: the phase II Exenatide-PD trial reported a motor benefit that persisted after washout (∼3.5-point between-group difference in MDS-UPDRS Part III), and the phase II LIXIPARK trial (lixisenatide) reported a significant 3.08-point between-group difference (95% CI 0.86–5.30; p = 0.007) favoring lixisenatide, whereas the larger, longer phase III Exenatide-PD3 trial, using an extended-release weekly formulation, found no significant effect on the same endpoint (adjusted coefficient 0.92; 95% CI −1.56 to 3.39; p = 0.47); oral semaglutide is under investigation in the ongoing phase II MOST-ABLE trial. In AD, the phase IIb liraglutide (ELAD) trial did not achieve statistical benefit on either its primary imaging endpoint (cerebral glucose metabolic rate; p = 0.14) or on most secondary cognitive measures, and the phase III semaglutide trials EVOKE and EVOKE+ did not meet their primary CDR-SB endpoint (estimated difference −0.08, 95% CI −0.35 to 0.20, p = 0.57 in EVOKE; 0.10, 95% CI −0.17 to 0.38, p = 0.46 in EVOKE+), despite biomarker signals including reductions in cerebrospinal fluid tau species and inflammatory markers. Comparative pharmacology reveals substantial heterogeneity in central nervous system penetration, receptor engagement, and systemic bioavailability across exenatide, liraglutide, semaglutide, and the imbalanced GLP-1/GIP co-agonist tirzepatide, complicating cross-agent extrapolation. Persistent challenges include separating direct neuroprotection from indirect metabolic and cardiovascular benefit, limited characterization of brain drug exposure, trial durations that may be short relative to the expected latency of a disease-modifying effect, and the absence of validated response biomarkers. We conclude that although the mechanistic and epidemiological rationale for GLP-1 RAs in neurodegeneration remains biologically plausible, current trial evidence does not yet support their use outside clinical trials, irrespective of comorbid diabetes status; future studies should prioritize earlier intervention, biomarker-guided patient selection, adequately powered subgroup analyses, and brain-penetrant formulations.

GLP-1 receptor agonistsParkinson's diseaseAlzheimer's diseasedisease-modifying therapy
ArticleOpen access20261citation· Semantic Scholar

Oxytocin restores cognitive function and attenuates neuroinflammation in chronic sleep-deprived aged rats

Frontiers in Aging Neuroscience · vol. 18 · 1742343-1742343

Background: Sleep is a fundamental biological process essential for maintaining mental, emotional, and physical health. Chronic sleep deprivation (SD), particularly in aging, is associated with oxidative stress, neuroinflammation, apoptosis, and cognitive and behavioral impairments. Oxytocin, a hypothalamic neuropeptide with reported antioxidant and anti-inflammatory properties, may modulate stress-related pathways; however, its role in mitigating SD-induced brain alterations remains unclear. This study investigated whether peripheral oxytocin administration influences brain and behavioral changes induced by chronic SD in aged rats. Methods: Male Sprague Dawley rats aged 20-24 months were divided into four groups: control, oxytocin-treated, SD, and SD with oxytocin treatment. Chronic SD was induced using a modified multiple platform method. Behavioral assessments were conducted to evaluate locomotor and exploratory activity. Serum cortisol was measured as a systemic stress marker, while brain tissues were analyzed for oxidative stress and inflammatory markers. Gene expression of Psen1 and Htr2a, oxytocin receptor protein levels, and histopathological changes, including gliosis and apoptosis, were also evaluated. Results: Chronic SD resulted in significant impairments in locomotor and exploratory behaviors, elevated serum cortisol levels, and increased oxidative stress and inflammatory markers. SD also altered the expression of Psen1 and Htr2a, reduced oxytocin receptor protein levels, and was associated with histological evidence of gliosis and apoptosis in brain tissues. Peripheral oxytocin administration attenuated many of these SD-induced alterations. However, because oxytocin was administered peripherally and central oxytocin levels or receptor engagement were not directly assessed, the findings cannot be interpreted as definitive evidence of direct central neuroprotection. Conclusion: The results suggest that oxytocin modulates stress responses, oxidative balance, and inflammatory pathways in aged rats subjected to chronic sleep deprivation. Although the precise central mechanisms remain unresolved, these findings support a potential role for oxytocin in mitigating SD-associated pathophysiological changes in aging and warrant further mechanistic studies to clarify its neuroprotective potential.

oxytocinchronic sleep deprivationagingneuroinflammation
ArticleOpen access2026

Tavapadon in Parkinson’s disease: D1/D5 receptor pharmacology, clinical evidence, and translational perspectives

Frontiers in Aging Neuroscience · vol. 18

Tavapadon is an oral, once-daily, non-catechol partial agonist selective for the D1 and D5 dopamine receptors and represents a mechanistically distinct option currently under clinical investigation for Parkinson disease (PD). This narrative review critically evaluates the biological rationale for D1/D5 receptor targeting, the pharmacological and preclinical development of tavapadon, and the accumulating phase 1–3 clinical evidence for its use as monotherapy in early PD and as adjunctive therapy in patients with motor fluctuations, while highlighting remaining evidence gaps and methodological limitations. A non-systematic literature search of PubMed/MEDLINE, Embase, ClinicalTrials.gov , and Scopus (through May 2026) was performed to identify representative and pivotal randomized controlled trials, pharmacokinetic/pharmacodynamic studies, and mechanistic preclinical investigations relevant to tavapadon and D1/D5 receptor agonism; this narrative approach was not intended to be exhaustive or fully reproducible in the manner of a systematic review. Mechanistically, selective stimulation of the direct striatal pathway together with submaximal intrinsic efficacy at the D1 receptor has been proposed, as a mechanistic hypothesis rather than a demonstrated clinical mechanism, to preserve antiparkinsonian benefit while limiting the receptor-signaling intensity implicated in levodopa-induced dyskinesia. In the phase 2 PARKWAY-II study and the now fully published phase 3 TEMPO-1 and TEMPO-2 trials, fixed- and flexible-dose tavapadon produced clinically meaningful improvements in MDS-UPDRS motor scores compared with placebo in early PD, and in the phase 3 TEMPO-3 trial, adjunctive tavapadon significantly increased daily good ON time and reduced OFF time in levodopa-treated patients with motor fluctuations; efficacy in all trials has been demonstrated only against placebo, with no head-to-head data against levodopa or other dopamine agonists. Adverse events were more frequent with tavapadon than placebo (approximately 72–76% versus 55% across TEMPO-2 and TEMPO-3), with nausea, headache, and dizziness the most common; no excess signal of impulse-control disorders relative to placebo was detected over the available 26–27-week controlled treatment period, and no clinically significant QTc prolongation was observed. The 58-week open-label TEMPO-4 extension, now reported in a peer-reviewed AAN abstract publication in Neurology alongside earlier interim conference data, suggests sustained benefit and a stable long-term levodopa requirement, but lacks a randomized control and cannot yet establish long-term safety superiority over existing agents. Tavapadon is a mechanistically novel candidate with preliminary evidence of efficacy; its ultimate clinical utility will depend on head-to-head trials and long-term safety data.

Parkinson's diseasedopamine D1 receptordopamine D5 receptormotor fluctuations
ArticleOpen access2026

A Systematic Comparative Review of Antipsychotic Efficacy and Safety in the Treatment of Hiccups

Neurosciences · vol. 31 (3) · 230-243

Objective: To evaluate and compare the safety and effectiveness of antipsychotic medications for the treatment of hiccups, thereby guiding clinicians toward evidence-based treatment guidelines. Hiccups are often benign and self-limiting; however, they can become persistent and intractable, adversely affecting the quality of life. Antipsychotics have been identified as a therapeutic option for the management of hiccups; however, the available evidence supporting their safety and efficacy has not been synthesized. Methods: This review utilized the revised Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The Cochrane Risk of Bias Assessment Tool was modified to evaluate the quality of the selected studies. The search strategy included terms related to or describing hiccups and antipsychotics. Research articles in English published between 1974 and March 2024 were searched in different databases. Duplicates and eligibility criteria were used to screen articles. Results: A search of Medline, Scopus, and Web of Science yielded 1537 articles, of which 1042 were retained after removing duplicates, and 16 met the inclusion criteria. The studies that met the inclusion criteria were all case reports, case series, or retrospective studies, with no randomized trials. A few antipsychotics have been shown to totally or partially alleviate hiccups. Nine studies reported that hiccups were completely resolved in patients treated with 10-25 mg oral and intramuscular chlorpromazine, 1-2 mg oral and intramuscular haloperidol, 2.5-10 mg oral olanzapine, 25-150 mg tetrabenazine, and 3 mg oral risperidone. Adverse events were documented in 7 of the studies. Conclusion: Chlorpromazine and olanzapine are effective antipsychotics for hiccup treatment. However, more evidence-based studies and controlled clinical trials are needed to confirm the efficacy and minimize the side effects. PROSPERO registration: (CRD42024511626).

hiccupsantipsychotic drugschlorpromazinehaloperidol
ArticleClosed2026

Meme‐Based Learning in Neuroanatomy: A Comparative Study on Effectiveness, Gender, and Student Performance Levels

Clinical Anatomy

Generation Z has different requirements, problems, expectations, and attitudes that they bring into the educational environment. Teachers have unprecedented challenges in addressing their needs and aspirations. Gamification involves integrating game-like elements into an existing educational framework. Rather than being a standalone teaching method, it serves as an instructional design approach. In this research, we investigated the impact of a meme-based approach in teaching various neuroanatomy topics and compared its effectiveness with traditional methods. In addition, we explored whether gender differences or students' academic levels influence their learning outcomes. The present research was conducted with third-year medical students enrolled in the neuroscience module at the College of Medicine, AlMaarefa University, Riyadh, Saudi Arabia, from September to December 2023, during the academic year 2023-2024. Students were instructed to create memes to aid in the comprehension and retention of anatomical facts and structures throughout the course. After each exam, we divide the questions into meme-related and non-meme-related categories. We then use the exam item analysis to compare the total student responses to the questions in the two categories, assess their performance, and compare the results between the male and female sections. Both male and female students showed significant improvement in their performance when responding to questions about meme-based material. Among high-achieving students, males showed a significant improvement in performance; however, the improvement among girls did not reach statistical significance. Conversely, both male and female students in the lower-performing group exhibited considerable improvements when interacting with meme-augmented topics. In conclusion, a meme-based approach significantly improved students' grades compared to the traditional approach; its effect was more pronounced among lower achievers and males. Although our findings suggest that male students may gain a greater advantage from this approach, the evidence for a gender-based moderating effect remains preliminary. The observed patterns require verification through larger, multicenter studies.

neuroanatomy educationgamificationGeneration Zgender differences in learning
ArticleOpen access20258citation· Semantic Scholar

Learning Disabilities in the 21st Century: Integrating Neuroscience, Education, and Technology for Better Outcomes

SAGE Open · vol. 15 (3)

Learning disabilities (LD) present substantial challenges for both affected individuals and society, often going under-recognized, leading to delays in diagnosis and inadequate interventions. These conditions are complex and caused by a mix of genetics, environment, and brain function. This can affect the sensory and mental information during processing, making learning more difficult. A systematic review of 19 selected studies was conducted using databases such as PubMed, Embase, Cochrane Library, and Web of Science. Studies were evaluated for risk of bias, and findings were synthesized to offer an integrated understanding of the etiology, pathophysiology, diagnostic complexities, and treatment strategies associated with LD. Key genetic and environmental risk factors were identified, and diagnostic challenges were explored, with an emphasis on the role of neurocognitive assessments and educational tools for accurate identification. The effectiveness of different treatments, such as educational programs, cognitive therapy, and novel technologies, was also assessed in terms of how well they help improve learning outcomes. The information processing theory was examined in depth, illustrating how disruptions in the processing of sensory and cognitive stimuli contribute to the learning difficulties observed in LD. The review also emphasizes the need for a team effort, bringing together parents, teachers, healthcare workers, and communities. This might provide vital support for people with LD. Advances in educational technology and cognitive training offer promising avenues for improving information processing and, consequently, educational outcomes. A holistic approach to diagnosis and intervention is essential for optimizing the quality of life and educational success of individuals with LD.

learning disabilitiesetiologygenetic risk factorsenvironmental risk factors
ReviewOpen access20253citation· Semantic Scholar

Is environmental enrichment effective in modulating autophagy markers in the brain exposed to adverse conditions? A systematic review

Frontiers in Cellular Neuroscience · vol. 19 · 1624500-1624500

Autophagy is a key regulator of cellular homeostasis and neuronal survival, particularly under adverse physiological conditions. Environmental enrichment (EE), a non-pharmacological intervention providing enhanced sensory, cognitive, and motor stimulation, may modulate autophagic processes in the brain. This systematic review aimed to synthesize preclinical findings on the effects of EE on autophagy markers in rodent models subjected to diverse adverse conditions. A literature search across PubMed, Scopus, ScienceDirect, and embase yielded eight eligible studies meeting inclusion criteria. EE was found to be generally associated with upregulation of key autophagic markers such as Beclin-1, LC3-II/LC3-I ratio, cathepsins, p62, p-TFEB, and LAMP-1 across brain regions including the cortex, hippocampus, and penumbral area. However, reductions in some markers were also observed, indicating that the modulatory effects of EE are context-dependent and may vary with disease model, brain region, or EE protocol duration. These findings suggest that EE holds promise as an adjunctive strategy to modulate autophagy and mitigate neurodegeneration, though heterogeneity in study design and outcomes warrants caution during interpretation. Further mechanistic and sex-specific studies are needed to clarify the therapeutic relevance of EE-induced autophagic modulation.

environmental enrichmentautophagyautophagy markersBeclin-1
ArticleOpen access20252citation· Semantic Scholar

Revolutionizing ALS Assessment: XGBoost Classification with Progressive Entropy Weighted-based Focal Loss on Gene Sequences

Journal of Disability Research · vol. 4 (1)

In recent times, the global rise in the prevalence rate of amyotrophic lateral sclerosis (ALS) has profoundly affected the welfare of several people in the world. ALS is a lethal neurodegenerative disease (NDD) that damages the nerve cells in the brain and spinal cord. Moreover, it removes the person’s capability of controlling muscle movements in the body. It is necessary to detect the disease earlier, to reduce the disease severity, and to enhance the life expectancy of the patients. Traditionally, ALS screening is handled by qualified physicians through blood tests, which is an expensive, painful, and time-consuming process. To resolve this limitation, several researchers focused on the ALS classification. Conversely, it have a few drawbacks, such as lack of accuracy and speed, overfitting of data, and noise handling tasks. For enhancing the classification of ALS, the proposed approach employs progressive entropy weighted-based focal loss (PEWFL)-XGBoost through the Kaggle ALS dataset. The XGBoost is used for the ability to manage missing data and speed. Nevertheless, it has certain limitations such as overfitting of data, hyperparameter tuning, and handling of smaller datasets. To resolve this, PEWFL is added to the XGBoost system to improve the classification performance. Correspondingly, the efficiency of the respective system is calculated using performance metrics to evaluate the performance of the research. Moreover, internal comparison with classical algorithms such as XGBoost, K-nearest neighbor, and random forest discloses the efficacy of the respective model. The proposed system is envisioned to contribute to molecular genetics and neuroscience research and assist neurologists in enhancing the diagnosis of ALS.

amyotrophic lateral sclerosisgene sequenceXGBoostneurodegenerative disease diagnosis
ArticleOpen access2025

The Crossroads of Neurology and Immunology: Exploring the Intricacies of Neuroimmune Interactions

World Journal of Neuroscience · vol. 15 (01) · 42-57

The concept of neuroimmune interactions has shown significant advancements over the years. Modern research has revealed many areas of connection between fields, which were previously viewed as distinct disciplines. For example, the nervous system can sense changes in the external environment and convey these changes through molecules and mediators with receptors in the immune system to modulate immune responses. Neuromediators can act on different receptors in the same group of cells, producing antipodal effects. Identification of the anti-inflammatory role of glucocorticoids highlighted that the body functions properly in an integrated manner. These interactions and crosstalk are not unidirectional, as the immune system can also influence various aspects of the nervous system, such as synaptic plasticity and fever. Strict integration of neuro-immuno-endocrine circuits is indispensable for homeostasis. Understanding these circuits and molecules can lead to advances in the understanding of various immune diseases, which will offer promising therapeutic options.

neuroimmune interactionsneuromodulatorsglucocorticoidsanti-inflammatory activity